Log in

1548 Genscript Biotech Corporation HKEX · Hong Kong

Genscript Biotech (1548) news

Genscript Biotech Corporation is a public biotech or pharmaceutical company listed on HKEX under the ticker 1548, recorded under Hong Kong. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Genscript Biotech news

We have not published a story on Genscript Biotech yet. When there is news, it will appear here.

Questions about Genscript Biotech

What is the ticker symbol of Genscript Biotech?

Genscript Biotech Corporation trades under the ticker 1548 on HKEX.

Where is Genscript Biotech listed?

Genscript Biotech Corporation is listed on HKEX. Our directory also records these other listings: GETTEX:G51; LS:A2ACSB; OTC:GNNSF.

Which country or territory is Genscript Biotech listed under?

Our directory records Genscript Biotech Corporation under Hong Kong.

What does Genscript Biotech do?

Our directory classifies Genscript Biotech Corporation as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Genscript Biotech?

The ISIN recorded for Genscript Biotech Corporation is KYG3825B1059.

Does aibio.space cover Genscript Biotech?

aibio.space lists Genscript Biotech Corporation among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Genscript Biotech?

Companies in our directory listed in the same country and business area as Genscript Biotech: CPBIO Holding Company, SinoMab Bioscience, China NT Pharma Group Co., Sirnaomics, China Regenerative Medicine International, China Resources Pharmaceutical Group.

Investor discussion: Genscript Biotech

Members talk about Genscript Biotech (1548). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Genscript Biotech, newest first. Each line links the filing it comes from.

  1. Listings

    Share consolidation: CHANGE IN BOARD LOT SIZE. Source

  2. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE. Source

  3. Financings

    Share or debt issue: PLACING OF NEW SHARES UNDER THE GENERAL MANDATE. Source

  4. Mergers

    Transaction under the Listing Rules: COMPLETION OF DISCLOSEABLE TRANSACTION AND TRANSACTION WITH CONNECTED PERSON AT SUBSIDIARY LEVEL IN RELATION TO TRANSFER OF SHARES OF PROBIO CAYMAN. Source

  5. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION AND TRANSACTION WITH CONNECTED PERSON AT SUBSIDIARY LEVEL IN REATION TO TRANSFER OF SHARES OF PROBIO CAYMAN. Source

  6. Financings

    Share or debt issue: COMPANY EXERCISES THE CONVERSION RIGHTS OF THE CONVERTIBLE BOND ISSUED BY PROBIO CAYMAN. Source

Press releases

Headlines of Genscript Biotech's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT: LEGEND ANNOUNCES PRELIMINARY SALES FOR CARVYKTI FOR THE QUARTER ENDED 30 SEPTEMBER 2026

  2. HKEXnews

    CHANGE IN BOARD LOT SIZE

  3. HKEXnews

    ANNOUNCEMENT PURSUANT TO RULE 13.10 OF THE LISTING RULES

  4. HKEXnews

    PASSING AWAY OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

  5. HKEXnews

    COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE

  6. HKEXnews

    PLACING OF NEW SHARES UNDER THE GENERAL MANDATE

  7. HKEXnews

    FIFTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

  8. HKEXnews

    CHANGE OF NAME OF PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE AND REGISTERED OFFICE IN CAYMAN ISLANDS

  9. HKEXnews

    INSIDE INFORMATION: PROPOSED SPIN-OFF AND SEPARATE LISTING OF PROBIO TECHNOLOGY LIMITED

  10. HKEXnews

    ANNOUNCEMENT OF UNAUDITED CONSOLIDATED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT: FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED 30 JUNE 2026 OF A LISTED ASSOCIATE - LEGEND BIOTECH CORPORATION

  12. HKEXnews

    VOLUNTARY ANNOUNCEMENT: LEGEND ANNOUNCES PRELIMINARY SALES FOR CARVYKTI FOR THE QUARTER ENDED 30 JUNE 2026

  13. HKEXnews

    VOLUNTARY ANNOUNCEMENT: LEGEND ESTABLISHES CLINICAL PROOF-OF-CONCEPT FOR LB2501, A POTENTIAL FIRST-IN-CLASS IN VIVO CD19/CD20 DUAL-TARGETING CAR-T, IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

  14. HKEXnews

    (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2026 AND (2) AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND THE ADOPTION OF THE AEMDNED MEMORANDUM AND ARTICLES OF ASSOCIATION

  15. HKEXnews

    GRANT OF RESTRICTED SHARE UNITS

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT: LEGEND ANNOUNCES LATE-BREAKING ORAL PRESENTATION AT EHA 2026 SHOWCASING INITIAL PHASE 1 IN VIVO CAR-T DATA WITH LB2501 IN NONHODGKIN LYMPHOMA (NHL)

  17. HKEXnews

    VOLUNTARY ANNOUNCEMENT: LEGEND PRESENTS FIRST-IN-HUMAN LB2102 RESULTS IN SOLID TUMORS AND NEW CARVYKTI DATA IN MULTIPLE MYELOMA AT ASCO 2026

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT: LEGEND ANNOUNCED PRESENTATIONS AT 2026 ASCO ANNUAL MEETING

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT: FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 31 MARCH 2026 OF A LISTED ASSOCIATE - LEGEND BIOTECH CORPORATION

  20. HKEXnews

    VOLUNTARY ANNOUNCEMENT: LEGEND ANNOUNCES PRELIMINARY SALES FOR CARVYKTI FOR THE QUARTER ENDED 31 MARCH 2026

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:1548 on TradingView.

Listing details

Genscript Biotech Corporation is a public biotech or pharmaceutical company listed on HKEX under the ticker 1548, recorded under Hong Kong. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Genscript Biotech Corporation
Ticker
1548
Listing
HKEX
Country or territory
Hong Kong
Business scope
Biotechnology
ISIN
KYG3825B1059
Other listed symbols
GETTEX:G51; LS:A2ACSB; OTC:GNNSF
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.